These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 2732616)
1. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests. Brenner B; Francis CW; Marder VJ J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616 [TBL] [Abstract][Full Text] [Related]
2. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. McCarron BI; Marder VJ; Francis CW Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661 [TBL] [Abstract][Full Text] [Related]
3. Validation, calibration, and specificity of quantitative D-dimer assays. Dempfle CE Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152 [TBL] [Abstract][Full Text] [Related]
4. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232 [TBL] [Abstract][Full Text] [Related]
5. Reactivity of fibrinogen derivatives with antisera to human fibrin D-dimer and its gamma-gamma chain remnant. Cierniewski CS; Janiak A; Nowak P; Augustyniak W Thromb Haemost; 1982 Aug; 48(1):33-7. PubMed ID: 7135342 [TBL] [Abstract][Full Text] [Related]
6. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain. Plow EF; Edgington TS J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807 [TBL] [Abstract][Full Text] [Related]
7. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Horan JT; Francis CW Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689 [TBL] [Abstract][Full Text] [Related]
8. Plasmic degradation of fibrinogen Paris I. Budzynski AZ; Marder VJ J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044 [TBL] [Abstract][Full Text] [Related]
9. Degradation of cross-linked fibrin by human leukocyte proteases. Francis CW; Marder VJ J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776 [TBL] [Abstract][Full Text] [Related]
10. Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers. Francis CW; Doughney K; Brenner B; Klingbiel K; Marder VJ Circulation; 1989 Mar; 79(3):666-73. PubMed ID: 2465100 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody to fibrin D-dimer (DD-3B6) recognizes an epitope on the gamma-chain of fragment D. Devine DV; Greenberg CS Am J Clin Pathol; 1988 May; 89(5):663-6. PubMed ID: 2451885 [TBL] [Abstract][Full Text] [Related]
12. Plasma cross-linked fibrin degradation product (XLFbDP) assays in an in vivo model of fibrinolysis. Rowbotham BJ; Whitaker AN; Masci PP Blood Coagul Fibrinolysis; 1990 Dec; 1(6):653-61. PubMed ID: 2133245 [TBL] [Abstract][Full Text] [Related]
13. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. Kornberg A; Francis CW; Marder VJ Blood; 1992 Aug; 80(3):709-17. PubMed ID: 1386260 [TBL] [Abstract][Full Text] [Related]
14. The detection of D-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody. Hart R; Bate I; Dinh D; Elms M; Bundesen P; Hillyard C; Rylatt DB Blood Coagul Fibrinolysis; 1994 Apr; 5(2):227-32. PubMed ID: 7519890 [TBL] [Abstract][Full Text] [Related]
15. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot]. Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722 [TBL] [Abstract][Full Text] [Related]
16. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen. Plow EF; Gramse M; Havemann K J Lab Clin Med; 1983 Dec; 102(6):858-69. PubMed ID: 6227673 [TBL] [Abstract][Full Text] [Related]
17. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Pfitzner SA; Dempfle CE; Matsuda M; Heene DL Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756 [TBL] [Abstract][Full Text] [Related]
18. Proceedings: Gamma'-dimer antibody and its specificity against fibrinogen, FR-a and carboxymethylated chains from fibrinogen and cross-linked fibrin. Clausen NT; Gormsen J Thromb Diath Haemorrh; 1975 Sep; 34(1):326. PubMed ID: 1188740 [No Abstract] [Full Text] [Related]
19. Measurement of autoantibodies against fibrinogen and fibrin degradation products by enzyme-linked immunoassay. Whitaker AN; McFarlane JR; Rowe EA; Lee K; Masci PP Thromb Haemost; 1985 Feb; 53(1):80-5. PubMed ID: 3992524 [TBL] [Abstract][Full Text] [Related]
20. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis. Alkjaersig N; Davies A; Fletcher A Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]